MI
OBIO icon

MMCAP International’s Orchestra BioMed OBIO Stock Holding History

MMCAP International’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-26,207
Closed -$288K – 135
2020
Q3 		$288K Buy
+26,207
New +$294K 0.07% 58

Other funds holding OBIO

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

MMCAP International's OBIO Position: Q4 2020 in Review

MMCAP International sold out of Orchestra BioMed (OBIO) in Q4 2020, closing a stake of 26,207 shares — an estimated $288K sold.

MMCAP International first reported a position in OBIO in Q3 2020 and held it in 1 quarter. The position peaked at $288K in Q3 2020. 46 funds tracked by Wall St. Rank hold OBIO as of Q4 2020.

  • MMCAP International reported no remaining Orchestra BioMed position as of Q4 2020 after selling out during the quarter.
  • MMCAP International sold 26,207 Orchestra BioMed shares in Q4 2020, an estimated $288K.
  • MMCAP International first reported a position in Orchestra BioMed in Q3 2020 and held it in 1 quarter.
  • MMCAP International's Orchestra BioMed position peaked at $288K in Q3 2020.
  • 46 funds tracked by Wall St. Rank held Orchestra BioMed as of Q4 2020.

Based on MMCAP International's 13F filing for Q4 2020, filed 16 Feb 2021.